ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 7,600 shares, a drop of 54.8% from the October 15th total of 16,800 shares. Based on an average daily trading volume, of 11,400 shares, the short-interest ratio is currently 0.7 days.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
A hedge fund recently bought a new stake in ProShares Ultra Nasdaq Biotechnology stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,000 shares of the exchange traded fund's stock, valued at approximately $288,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.31% of ProShares Ultra Nasdaq Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).
ProShares Ultra Nasdaq Biotechnology Stock Performance
BIB traded down $1.01 during trading on Wednesday, hitting $61.75. 16,836 shares of the company's stock traded hands, compared to its average volume of 23,643. The company's 50 day simple moving average is $63.75 and its two-hundred day simple moving average is $61.84. ProShares Ultra Nasdaq Biotechnology has a 12-month low of $42.42 and a 12-month high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The firm also recently announced a dividend, which was paid on Wednesday, October 2nd. Shareholders of record on Wednesday, September 25th were paid a dividend of $0.1528 per share. This is an increase from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.04. The ex-dividend date was Wednesday, September 25th.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
